Pharma BD Deal Intelligence
Franchise-adjacent, de-risked oral EGFR asset with 1L expansion upside
Full analysis, sources & comparables →AstraZeneca entered an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for lung cancer. AstraZeneca acquires worldwide rights to develop and commercialize the drug, paying Dizal $600M upfront plus up to $900M in development, regulatory and sales milestones and tiered royalties on global sales. Zegfrovy is already approved in China and the U.S. for adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations after platinum-based chemotherapy; Dizal recently reported first-line Phase III WU-KONG28 results at ASCO 2026 (published in NEJM). The transaction is expected to close in H2 2026, subject to customary conditions and regulatory clearances.
Non-small cell lung cancer driven by EGFR exon 20 insertion mutations is a distinct molecular subset that responds poorly to classical EGFR tyrosine-kinase inhibitors. Zegfrovy (sunvozertinib) is an oral irreversible EGFR inhibitor approved in China and the U.S. for locally advanced/metastatic exon-20-insertion NSCLC after platinum chemotherapy; the global WU-KONG28 Phase III trial in first-line exon-20-insertion NSCLC was positive (ASCO 2026; NEJM).
Amivantamab (Rybrevant, J&J) - an intravenous EGFR x MET bispecific antibody - is the principal approved competitor in exon-20-insertion NSCLC. Mobocertinib (Exkivity, Takeda), an oral exon-20 TKI, was withdrawn in 2023-2024 after a failed confirmatory trial. Zipalertinib (Taiho/Cullinan), another oral exon-20 TKI, is in late-stage development. Sunvozertinib's oral, once-daily profile differentiates it from IV amivantamab. AstraZeneca's Tagrisso (osimertinib) covers classical EGFR NSCLC, making Zegfrovy a franchise-adjacent addition.
AstraZeneca gains worldwide rights to develop and commercialize Zegfrovy (sunvozertinib) for $600M upfront plus up to $900M in development, regulatory and sales milestones and tiered royalties; expected to close H2 2026.
AZ adds a marketed exon-20-insertion oral TKI with a positive first-line Phase III, complementing Tagrisso; $600M upfront is modest for a launched asset with label-expansion upside.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd (this deal) | 2026 | $1.5B | 73 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2026 deals · AstraZeneca PLC deals · Oncology deals